Ovarian Cancer Drugs Market
Ovarian Cancer Drugs Market - Global Industry Assessment & Forecast
#
Pages:
248
Base Year:
2023
Apr - 2024
Format:
Report Code:
VMR-2462
Segments Covered
By
Therapeutic Class PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors
-
By
Treatment Chemotherapy, Radiation Therapy, Hormonal Therapy, Targeted Therapy, Other Treatments
-
By
End User Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2023 |
| Forecast
Years:
|
2024 - 2032 |
 Historical
Years:
|
2018 - 2022 |
 Revenue
2023: |
USD 3.7 Billion |
 Revenue 2032:
|
USD 6.67 Billion |
 Revenue CAGR
(2024 - 2032): |
6.8% |
Fastest Growing Region (2024 -
2032)
|
Asia Pacific |
Largest Region (2023):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
Ovarian Cancer Drugs Market Segment Analysis
- Ovarian Cancer Drugs Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Ovarian Cancer Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Ovarian Cancer Drugs End User Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
-
Regional Outlook (Revenue, USD Billion/Million, 2018 - 2030)
- North America
-
North America Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
-
North America Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
-
North America Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S.
- U.S. Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- U.S. Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- U.S. Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.S. Ovarian Cancer Drugs Market, by Therapeutic Class
- Canada
- Canada Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Canada Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Canada Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Canada Ovarian Cancer Drugs Market, by Therapeutic Class
-
Mexico
- Mexico Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Mexico Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Mexico Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Mexico Ovarian Cancer Drugs Market, by Therapeutic Class
-
North America Ovarian Cancer Drugs Market, by Therapeutic Class
- Europe
-
Europe Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
-
Europe Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
-
Europe Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U. K.
- U.K. Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- U.K. Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- U.K. Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- U.K. Ovarian Cancer Drugs Market, by Therapeutic Class
- France
- France Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- France Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- France Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- France Ovarian Cancer Drugs Market, by Therapeutic Class
-
Germany
- Germany Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Germany Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Germany Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Germany Ovarian Cancer Drugs Market, by Therapeutic Class
-
Italy
- Italy Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Italy Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Italy Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Italy Ovarian Cancer Drugs Market, by Therapeutic Class
-
Spain
- Spain Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Spain Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Spain Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Spain Ovarian Cancer Drugs Market, by Therapeutic Class
-
Rest of Europe
- Rest of Europe Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Rest of Europe Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Rest of Europe Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Europe Ovarian Cancer Drugs Market, by Therapeutic Class
-
Europe Ovarian Cancer Drugs Market, by Therapeutic Class
- Asia Pacific
-
Asia Pacific Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
-
Asia Pacific Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
-
Asia Pacific Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- China
- China Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- China Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- China Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- China Ovarian Cancer Drugs Market, by Therapeutic Class
- Japan
- Japan Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Japan Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Japan Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Japan Ovarian Cancer Drugs Market, by Therapeutic Class
-
Germany
- Germany Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Germany Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Germany Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Germany Ovarian Cancer Drugs Market, by Therapeutic Class
-
India
- India Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- India Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- India Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- India Ovarian Cancer Drugs Market, by Therapeutic Class
-
South Korea
- South Korea Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- South Korea Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- South Korea Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South Korea Ovarian Cancer Drugs Market, by Therapeutic Class
-
South East Asia
- South East Asia Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- South East Asia Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- South East Asia Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South East Asia Ovarian Cancer Drugs Market, by Therapeutic Class
-
Rest of Asia Pacific
- Rest of Asia Pacific Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Rest of Asia Pacific Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Rest of Asia Pacific Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Asia Pacific Ovarian Cancer Drugs Market, by Therapeutic Class
-
Asia Pacific Ovarian Cancer Drugs Market, by Therapeutic Class
- Latin America
-
Latin America Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
-
Latin America Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
-
Latin America Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Brazil
- Brazil Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Brazil Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Brazil Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Brazil Ovarian Cancer Drugs Market, by Therapeutic Class
- Argentina
- Argentina Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Argentina Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Argentina Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Argentina Ovarian Cancer Drugs Market, by Therapeutic Class
-
Rest of Latin America
- Rest of Latin America Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Rest of Latin America Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Rest of Latin America Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Latin America Ovarian Cancer Drugs Market, by Therapeutic Class
-
Latin America Ovarian Cancer Drugs Market, by Therapeutic Class
- Middle East & Africa
-
Middle East & Africa Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
-
Middle East & Africa Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
-
Middle East & Africa Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- GCC Countries
- GCC Countries Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- GCC Countries Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- GCC Countries Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- GCC Countries Ovarian Cancer Drugs Market, by Therapeutic Class
- South Africa
- South Africa Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- South Africa Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- South Africa Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- South Africa Ovarian Cancer Drugs Market, by Therapeutic Class
-
Rest of Middle East & Africa
- Rest of Middle East & Africa Ovarian Cancer Drugs Market, by Therapeutic Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- PD-L1 Inhibitors
- Rest of Middle East & Africa Ovarian Cancer Drugs Market, by Treatment
- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Targeted Therapy
- Other Treatments
- Rest of Middle East & Africa Ovarian Cancer Drugs Market, by End User
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Rest of Middle East & Africa Ovarian Cancer Drugs Market, by Therapeutic Class
-
Middle East & Africa Ovarian Cancer Drugs Market, by Therapeutic Class
- North America
Vantage Market
Research | 20-May-2024
FAQ
Frequently Asked Question
What is the global demand for Ovarian Cancer Drugs in terms of revenue?
-
The global Ovarian Cancer Drugs valued at USD 3.7 Billion in 2023 and is expected to reach USD 6.67 Billion in 2032 growing at a CAGR of 6.8%.
Which are the prominent players in the market?
-
The prominent players in the market are F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline PLC (UK), Immunogen Inc. (U.S.), Astrazeneca (UK), Merck KGaA (Germany), Oasmia Pharmaceutical AB (Sweden), Clovis Oncology Inc. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Eli Lilly and Company (U.S.), Aravive Biologics (U.S.), Allarity Therapeutics (U.S.).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 6.8% between 2024 and 2032.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Ovarian Cancer Drugs include
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Ovarian Cancer Drugs in 2023.
